ctDNA Identifies Acquired Resistance Mechanisms to Savolitinib in MET+ Gastric Cancer
An early trial of AstraZeneca’s MET inhibitor savolitinib in gastric cancer revealed mutations that confer drug resistance.
For press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org


Powering progress to defeat stomach cancer.


Powering progress to defeat stomach cancer.
MORE INFODONATEDONATEMORE INFO